{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:27:01Z","timestamp":1778261221653,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"CSL Behring"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle Nerve"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1002\/mus.25107","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T14:10:53Z","timestamp":1458310253000},"page":"856-863","source":"Crossref","is-referenced-by-count":27,"title":["Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy"],"prefix":"10.1002","volume":"54","author":[{"given":"Hans D.","family":"Katzberg","sequence":"first","affiliation":[{"name":"Division of Neurology; University Health Network Toronto General Hospital; 200 Elizabeth Street, 5ES-306 Toronto Ontario M5G 2C4 Canada"},{"name":"University of Toronto; Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilija","family":"Rasutis","sequence":"additional","affiliation":[{"name":"Division of Neurology; University Health Network Toronto General Hospital; 200 Elizabeth Street, 5ES-306 Toronto Ontario M5G 2C4 Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"Division of Neurology; University Health Network Toronto General Hospital; 200 Elizabeth Street, 5ES-306 Toronto Ontario M5G 2C4 Canada"},{"name":"University of Toronto; Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,3]]},"reference":[{"key":"10.1002\/mus.25107-BIB0001|mus25107-cit-0001","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/WCO.0b013e328364caca","article-title":"Multifocal motor neuropathy","volume":"26","author":"Guimar\u00f1es-Costa","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1002\/mus.25107-BIB0002|mus25107-cit-0002","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.autrev.2014.08.018","article-title":"Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1002\/mus.25107-BIB0003|mus25107-cit-0003","first-page":"567","article-title":"Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment","volume":"10","author":"Lawson","year":"2014","journal-title":"Neuropsychiatr Dis Treatm"},{"key":"10.1002\/mus.25107-BIB0004|mus25107-cit-0004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.expneurol.2012.03.023","article-title":"A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies","volume":"235","author":"Uncini","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1002\/mus.25107-BIB0005|mus25107-cit-0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","article-title":"A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy","volume":"18","author":"Hahn","year":"2013","journal-title":"J Periph Nerv Syst"},{"key":"10.1002\/mus.25107-BIB0006|mus25107-cit-0006","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1212\/WNL.43.3_Part_1.537","article-title":"High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy","volume":"43","author":"Nobile-Orazio","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/mus.25107-BIB0007|mus25107-cit-0007","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"Berg","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mus.25107-BIB0008|mus25107-cit-0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1002\/mus.25107-BIB0009|mus25107-cit-0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1002\/mus.25107-BIB0010|mus25107-cit-0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10072-010-0352-z","article-title":"Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report","volume":"31","author":"Dacci","year":"2010","journal-title":"Neurol Sci"},{"key":"10.1002\/mus.25107-BIB0011|mus25107-cit-0011","unstructured":"CSL Behring receives FDA approval of Hizentra, first 20 percent subcutaneous immunoglobulin therapy http:\/\/www.cslbehring-us.com\/s1\/cs\/enus\/1154272074489\/news\/1255923403239\/prdetail.html 2015"},{"key":"10.1002\/mus.25107-BIB0012|mus25107-cit-0012","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"Smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J Periph Nerv Syst"},{"key":"10.1002\/mus.25107-BIB0013|mus25107-cit-0013","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1002\/mus.25107-BIB0014|mus25107-cit-0014","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1002\/mus.25107-BIB0015|mus25107-cit-0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/mus.25107-BIB0016|mus25107-cit-0016","first-page":"458231","article-title":"High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis","volume":"2014","author":"Patrick","year":"2014","journal-title":"Case Rep Rheumatol"},{"key":"10.1002\/mus.25107-BIB0017|mus25107-cit-0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","article-title":"Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision","volume":"15","author":"Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy","year":"2010","journal-title":"J Periph Nerve Syst"},{"key":"10.1002\/mus.25107-BIB0018|mus25107-cit-0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25107-BIB0019|mus25107-cit-0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890109002092","article-title":"The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies","volume":"33","author":"Furlong","year":"2001","journal-title":"Ann Med"},{"key":"10.1002\/mus.25107-BIB0020|mus25107-cit-0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1191\/135245899678846131","article-title":"The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis","volume":"5","author":"Sharrack","year":"1999","journal-title":"Mult Scler"},{"key":"10.1002\/mus.25107-BIB0021|mus25107-cit-0021","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Periph Nerv Syst"},{"key":"10.1002\/mus.25107-BIB0022|mus25107-cit-0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1756285614563056","article-title":"Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction","volume":"8","author":"Hadden","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1002\/mus.25107-BIB0023|mus25107-cit-0023","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00415-014-7444-2","article-title":"SCIg and Chronic Dysimmune Neuropathies Italian Network. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study","volume":"261","author":"Cocito","year":"2014","journal-title":"J Neurol"},{"key":"10.1002\/mus.25107-BIB0024|mus25107-cit-0024","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.12513","article-title":"Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1002\/mus.25107-BIB0025|mus25107-cit-0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10875-013-9876-3","article-title":"Bioavailability of IgG administered by the subcutaneous route","volume":"33","author":"Berger","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1002\/mus.25107-BIB0026|mus25107-cit-0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3810\/pgm.2013.11.2712","article-title":"Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immune deficiency","volume":"125","author":"Landersdorfer","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1002\/mus.25107-BIB0027|mus25107-cit-0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF01541739","article-title":"Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home","volume":"15","author":"Brennan","year":"1995","journal-title":"J Clin Immunol"},{"key":"10.1002\/mus.25107-BIB0028|mus25107-cit-0028","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"103","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1002\/mus.25107-BIB0029|mus25107-cit-0029","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jns.12141","article-title":"Rasch-built Overall Disability Scale for Multifocal Motor Neuropathy (MMN-RODS)","volume":"20","author":"Vanhoutte","year":"2015","journal-title":"J Periph Nerv Syst"},{"key":"10.1002\/mus.25107-BIB0030|mus25107-cit-0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1710-1492-10-23","article-title":"Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada","volume":"10","author":"Gerth","year":"2014","journal-title":"Allerg Asthma Clin Immunol"},{"key":"10.1002\/mus.25107-BIB0031|mus25107-cit-0031","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10072-014-1632-9","article-title":"Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis","volume":"35","author":"Lazzaro","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1002\/mus.25107-BIB0032|mus25107-cit-0032","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1017\/S0317167100014359","article-title":"Home IVIG for CIDP: a focus on patient centred care","volume":"40","author":"Katzberg","year":"2013","journal-title":"Can J Neurol Sci"}],"container-title":["Muscle & Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25107","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/mus.25107\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T04:35:04Z","timestamp":1625459704000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.25107"}},"subtitle":["SCIg for Treatment of MMN"],"short-title":[],"issued":{"date-parts":[[2016,8,3]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/mus.25107","archive":["Portico"],"relation":{},"ISSN":["0148-639X"],"issn-type":[{"value":"0148-639X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8,3]]}}}